Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-O...
September 20 2017 - 8:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced its
participation at two upcoming healthcare investor conferences in
September.
- Cantor Fitzgerald Global Healthcare
Conference. On Wednesday, September 27, 2017, Keith
Orford, M.D., Ph.D., Senior Vice President of Clinical Development,
will present a corporate update at 9:10 a.m. EDT at the Cantor
Fitzgerald Global Healthcare Conference in New York
City.
- Leerink Partners Immuno-Oncology
Roundtable. On Thursday, September 28, 2017, Dr.
Orford will participate in a fireside chat to discuss recent
corporate developments at the Leerink Partners Immuno-Oncology
Roundtable being held in New York City at 8:30 a.m. EDT.
The presentations will be webcast live, and available for replay
for up to 30 days at www.calithera.com in the Investor Relations
section.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is a potent, selective, reversible and orally
bioavailable inhibitor of glutaminase. CB-839 takes advantage of
the pronounced dependency many cancers have on the nutrient
glutamine for growth and survival. It is currently being evaluated
in Phase 2 clinical trials in combination with standard of care
agents. CB-1158 is a first-in-class immuno-oncology metabolic
checkpoint inhibitor targeting arginase, a critical
immunosuppressive enzyme responsible for T-cell suppression by
myeloid-derived suppressor cells. Arginase depletes arginine,
a nutrient that is critical for the activation, growth and survival
of the body’s cancer-fighting immune cells, known as cytotoxic
T-cells. CB-1158 is being developed in collaboration with
Incyte Corporation and is currently in a Phase 1 clinical
trial. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please
visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the
timing of Calithera’s clinical trials, the clinical and commercial
potential of its product candidates, Calithera’s ability to fund
its clinical programs, and Calithera’s receipt of clinical data
from its clinical trials. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
The potential product candidates that Calithera develops may
not progress through clinical development or receive required
regulatory approvals within expected timelines or at all. In
addition, clinical trials may not confirm any safety, potency or
other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to patients
or successfully commercialized. The failure to meet
expectations with respect to any of the foregoing matters may have
a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Contact:Jennifer
McNealeyir@Calithera.com 650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024